S3-13: Lipids: Looking forward to
|
|
- Flora Sims
- 6 years ago
- Views:
Transcription
1 S3-13: Lipids: Looking forward to 2018 Heart and Stroke Clinical Update Dec 2017 Robert Hegele MD, FRCPC, FACP Distinguished University Professor Endocrinologist, University Hospital Western University, London ON hegele@robarts.ca
2 Faculty/Presenter Disclosure Faculty: Rob Hegele Relationships with commercial interests: Grants/Research Support: Amgen, ISIS, Pfizer, Lilly, Aegerion Speakers Bureau/Honoraria: Valeant, Amgen, Aegerion. Consulting Fees: Amgen, Sanofi, Valeant, Aegerion, Lilly Other: N/A
3 Question 1 1. What is the current Canadian lipid target for high-risk patients? A) LDL-C < 2.0 mmol/l B) non-hdl-c < 2.6 mmol/l C) apo B < 0.8 g/l D) all of the above 3
4 Question 2 2. What is the main mechanism of statin benefit? A) LDL-C reduction B) anti-inflammatory C) anti-thrombotic D) endothelial relaxation E) all of the above 4
5 Question 3 3. What is/are the current indication(s) for PCSK9 inhibition in Canada? A) familial hypercholesterolemia B) atherosclerotic cardiovascular disease, not controlled C) statin intolerance D) A and B only E) A, B and C 5
6 Objectives 1. To review current Canadian Lipid Guidelines 2. To appreciate the role of established treatments 3. To evaluate the potential of recently approved lipid treatments
7 7
8 Issues in the 2016 guidelines keep LDL-C targets < 2.0 mmol/l lower is better non-fasting lipids to screen non-hdl-c and apo B are alternate targets Framingham or cardiovascular age statins remain foundational Rx non-statins: ezetimibe OK; niacin, fibrates less so PCSK9-inhibitors Anderson et al. Can J Cardiol 2016; 32:
9 2016 Lipid Guidelines Anderson et al. Can J Cardiol 2016; 32:
10 2012 CCS Dyslipidemia Guidelines Update Table 7. Expected Benefit of Health Behaviour Changes Intervention (minimal dose for effect) Dietary cholesterol intake 98 < 300 mg/day (NCEP step I diet) < 200 mg/day (NCEP step II diet) Expected Outcome LDL-C 10-12% 12-16% Saturated fats < 7% of daily caloric intake 107 LDL-C 5-10%; CVD mortality 14% Phytosterols 1-2 g/day 100 LDL-C 5-8% Soy proteins with isoflavones 25g/day 101 LDL-C 3-5% Viscous fibre 10 g/day 102 LDL-C 3-5% Nuts g/day 103 LDL-C 5-7%, TG 5-10% Portfolio type diet 104 LDL-C 8-14% Mediterranean type diet 105 DASH (Dietary Approaches to Stop Hypertension) diet 106 LDL-C 5-10%; CVD mortality CVD mortality in those with hypertension Anderson TJ, Gregoire J et al., Can J Cardiol 2013 Feb;29(2): /12/2017 Copyright 2013, Canadian Cardiovascular Society 10
11 2012 CCS Dyslipidemia Guidelines Update Table 7. Expected Benefit of Health Behaviour Changes Intervention (minimal dose effect) Expected Outcome Moderated Alcohol intake 1-2 drinks/day HDL 5-10%, CVD events Weight loss and reduction of abdominal obesity 42 LDL-C, HDL, TG, 5-10% of body weight loss cardiometabolic risk Omega g of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)/day TG 25-30% in pts. with TG Exercise 109, min/day moderate to vigorous intensity HDL 5-10%, CVD events Smoking cessation HDL, CVD events Anderson TJ, Gregoire J et al., Can J Cardiol 2013 Feb;29(2): /12/2017 Copyright 2013, Canadian Cardiovascular Society 11
12 2016 Lipid Guidelines Treatment Targets: LDL-C consistently <2.0 mmol/l or >50% reduction Consider <1.8 mmol/l in patients with clinical atherosclerosis Apo B 0.80 g/l or non-hdl-c 2.6 mmol/l be considered as alternative treatment targets Statin Indicated Conditions (those who will benefit the most): Clinical atherosclerosis* Abdominal aortic aneurysm Most diabetes mellitus CKD (age >50 years) LDL-C 5.0 mmol/l *Clinical atherosclerosis, i.e. previous MI, or coronary revascularization by PCI or CABG surgery, other arterial revascularization procedures, angina pectoris, cerebrovascular disease including TIA, or peripheral arterial disease (claudication and/or ABI <0.9). Anderson et al. Can J Cardiol 2016; 32:
13 Non-fasting lipids Langsted et al. Circulation 2008;118:
14 Non-HDL-C as an alternate target non-hdl-c = TC HDL-C 14/12/
15 Risk assessment Here's your personalized Heart & Stroke Risk Assessment. Having trouble viewing our ? View it online. Your Personalized Risk Assessment Report Your life expectancy* is: *Based on specific lifestyle risk factors. Read more. 88 years A Canadian male your age lives an average of 82 years. Your life expectancy is higher than other people of your age group and gender. You can still make positive changes to improve your cardiac health and protect what matters. The Heart and Stroke Foundation is here to support you and your family, every step of the way. Risk factors you cannot control Non-controllable risk factors for heart disease and stroke include your age, gender, ethnicity and family history. While our researchers find ways to stop heart disease and stroke before they happen, we've uncovered realistic ways so you can minimize your risks. FAMILY HISTORY See how your family history is affecting your life today, and how to take action with powerful steps that help break the cycle of heart disease and stroke. READ MORE Anderson et al. Can J Cardiol 2016; 32:
16 Reduced all-cause mortality with statins LDL 4.4 mmol/l LDL-C 3.1 mmol/l 4S Investigators Lancet 2004; 364:771-7.
17 Reduced all-cause mortality with statins HR 0.80 (0.67 to 0.97, P=0.02) LDL-C 2.8 mmol/l LDL-C 1.8 mmol/l 20 mg N Engl J Med 2008; 359:
18 HOPE-3 LDL-C 3.2 mmol/l LDL-C 2.4 mmol/l 10 mg N Engl J Med 2016; 374:
19 Reduced all-cause mortality with statins Collins et al. Lancet Sep 8. pii: S (16)31357
20 Reduced major vascular events with statins CTTC 2016; 25 RCTs of statins; >170,000 patients Lancet 2016 Sep 8; doi /S (16)
21 LDL-C and CHD risk
22 Benefits vs risks of lowering LDL-C with statins 10,000 patients receiving effective statin therapy for 5 years and lowered LDL-C by 2 mmol/l would result in: Major vascular events prevented 1,000 (secondary prevention patients) Muscle pain or weakness Myopathy (symptoms + CK > 10xULN) Rhabdomyolysis (if statin not stopped upon myopathy) Newonset diabetes Haemorrhagic stroke ~ 5 ~ 1 ~ 50 ~ 5 Based on CTT Collaboration meta-analyses of RCTs. Includes 22 trials (135,000 patients) comparing routine statin therapy to no routine statin therapy and 5 trials (40,000 patients) comparing more versus less intensive statin therapy. Collins R et al (2016) Lancet pii: S (16) doi: /S (16) [Epub ahead of print] Cholesterol Treatment Trialists Collaboration (2016)
23 CLINICAL ATHEROSCLEROSIS Myocardial infarction, acute coronary syndromes Stable angina, documented coronary disease by angiography (>10% stenosis) Stroke, TIA, documented carotid disease Peripheral artery disease, claudication and/or ABI <0.9 ABDOMINAL AORTIC ANEURYSM Statin indicated conditions Abdominal aorta >3.0 cm or Previous aneurysm surgery DIABETES MELLITUS 40 years of age or >15 years duration and age 30 years or Microvascular complications CHRONIC KIDNEY DISEASE >3 months duration and ACR >3.0 mg/mmol or egfr <60 ml/min/1.73m 2 LDL-C 5.0 MMOL/L LDL-C 5.0 mmol/l or Documented familial hypercholesterolemia Excluded 2 nd causes Canadian Journal of Cardiology DOI: ( /j.cjca ) Anderson et al. Can J Cardiol 2016; 32:
24 Statin doses and efficacy Am J Cardiol 2003; 92:
25 Statin discontinuation = reduced survival Side effects are the most common reason patients discontinue statins 1 Survival is reduced in patients who discontinue, even compared to those on non-daily statin doses 2 Survival (%) Statin continued/daily dose Statin continued/non-daily dose Statin discontinued Years 1. Cohen et al. J Clin Lipidol 2012;6: Mampuya et al. Am Heart J 2013;166:
26 Statin intolerance 1) statins not withheld on the basis of a potential, small risk of new-onset DM (Strong/Very Low). 2) evaluate purported statin-associated symptoms systematically, observe during cessation, reinitiation (same or switch), altered dosing frequency to find a tolerated, statin-based therapy. (Strong/Very Low). 3) we do not recommend vitamins, minerals or supplements for symptoms of myalgia perceived to be statin-associated. (Strong/Very Low).
27 Approach to the statin intolerant patient 1. Rechallenge with another statin - better tolerated: fluva, prava 2. Alternating day statin - most efficacious: rosuva 3. Use a different lipid-lowering class - CAI: ezetimibe - resin: cholestyramine, colesevalam - fibrate? 4. Coenzyme Q10: mg daily 5. Vitamin D (1000 IU daily) Joy TR, Hegele RA. Ann Intern Med 2009; 150:
28 Think twice about statins limited life expectancy limited QOL elderly/frail low CV risk end-stage renal disease end-stage CHF polypharmacy 28
29 Statins: summary - proven, evidence-based, life-saving years real-world experience - first line Rx to reach targets - 5 statin-eligible conditions + intermediate risk - benefits >>> risks in properly selected patients - encourage compliance 29
30 IMPROVE-IT: Primary Endpoint Intention-To-Treat Cardiovascular death, MI, documented unstable angina requiring rehospitalization, coronary revascularization ( 30 days), or stroke Hazard Ratio, (95% CI, ) p=0.016 Simvastatin: 34.7% events Mean LDL-C = 1.8 mmol/l NNT*= 50 Event Rate (%) Simvastatin/Ezetimibe: 32.7% events Mean LDL-C = 1.4 mmol/l * NNT = Number Needed to Treat Time since randomization (years) 7-year event rates Cannon CP et al, N Engl J Med 2015;372:
31 Gemfibrozil MCVE N Engl J Med 1999;341: 410-8
32 ACCORD-Lipid: MACE
33 Fibrates: patients with high TG-low HDL-C 33 N Engl J Med 2010; 363:
34 AIM-HIGH: niacin on background statin 34
35 Current Combination Therapy on Top of Statins for LDL Lowering BILE ACID SEQUESTRANTS No evidence of cardiovascular benefit on top of statin May improve glycemia EZETIMIBE FENOFIBRATE NIACIN Modest additional cardiovascular benefit as add-on to statin (IMPROVE-IT) Does not generally lower LDL No evidence of benefit in recent large studies (FIELD, ACCORD LIPID) Not well tolerated; may cause infection and bleeding No evidence of cardiovascular benefit on top of statin (HPS2- THRIVE, AIM HIGH) HPS2-THRIVE Collaborative Group. N Engl J Med 2014;371: Keech A et al, Lancet 2005 Nov 26;366(9500): ACCORD Study Group. N Engl J Med 2010;362: Genest J et al, Can J Cardiol 2006; 22(10):863:868 Anderson TJ et al, Canadian Journal of Cardiology 2016; doi: /j.cjca
36 CVD end point reduction Drug class No background statin Bile acid resins Yes (LRC-CPPT) With background statin Not done Ezetimibe Not done Yes (SHARP; IMPROVE-IT) Fibrates Yes (HHS, VA-HIT) No (ACCORD, FIELD) Niacin Yes (CDP) No (AIM-HIGH, HPS2) PCSK9i No Yes (FOURIER, SPIRE-2) Pending ODYSSEY- OUTCOMES
37 Case report 1-34 year-old truck driver, 2 o CHD prevention - father & 2 uncles: fatal MIs <50 years - age 29: TC and LDL-C = 10.6 and 8.5 mmol/l - age 33: - AMI - diffuse CAD - three stents placed - Rx: atorvastatin 80 mg, ezetimibe 10 mg, ramipril 5 mg, clopidogrel 75 mg, metoprolol 25 mg, ASA 81 mg Yuan et al. CMAJ 2006; 174:
38 On exam
39 Case report 1 date meds TC TG LDL-C HDL-C 1997 none atorvastatin 80 mg rosuvastatin 40 mg + ezetimibe 10 mg above 2 + niacin ER 2000 mg above rosuvastatin 40 mg + ezetimibe 10 mg + evolocumab 140 mg q2wk
40 Where did PCSK9 inhibitors come from? 40
41 Emerging lipid therapies Proprotein
42 Emerging lipid therapies Proprotein Convertase
43 Emerging lipid therapies Proprotein Convertase
44 Emerging lipid therapies Proprotein Convertase Subtilisin
45 Emerging lipid therapies Proprotein Convertase Subtilisin Kexin
46 Emerging lipid therapies Proprotein Convertase Subtilisin Kexin 9
47 PCSK9 inhibitors - very potent LDL-C reduction: 55-75% - non-statin mechanism - mabs: sc q2 or q4 wk - 2 approved agents: alirocumab, evolocumab - 20% reduced MACE with evolocumab
48 Terminology of Monoclonal Antibodies Source (% human protein) Mouse (0% human) Chimeric (65% human) Humanized (> 90% human) Human (100% human) Generic suffix: -omab -ximab -zumab -umab High Potential for immunogenicity Low 1. Weiner LM. J Immunother. 2006;29:1-9.; 2. Yang XD, et al. Crit Rev Oncol Hematol. 2001;38:17-23.; 3. Lonberg N. Nat Biotechnol. 2005;23: ; 4. Gerber DE. Am Fam Physician. 2008;77:
49 Alirocumab: ODYSSEY COMBO II Alirocumab Maintained Consistent LDL-C Reductions over 104 Weeks 120 On-treatment analysis of LDL-C levels Ezetimibe Alirocumab Calculated LDL-C, mg/dl, LS mean (SE) % -19.7% -30.5%* -32.4%* -52.3% -52.0% -17.0% -48.9% -32.0%* Weeks Values above and below the data points indicate the percentage reduction from baseline, with percentage differences indicated by the values by the arrows (*all comparisons were P<0.0001). Conversion factor : For values in mmol/l divide mg/dl by Shahawy et al, Presented at the National Lipid Association Scientific Sessions, May , New Orleans, LA, USA. 49
50 ODYSSEY Long Term*: LDL Cholesterol *All patients on background of high-dose or maximally-tolerated statin ± other lipidlowering therapy 4 Placebo LDL-C, LS mean (SE), mmol/l Alirocumab 150 mg Q2W 3.1 mmol/l 61.9% (95% CI %, p< 0,001) 1.3 mmol/l 3.2 mmol/l 1.5 mmol/l mmol/l Intent-to-treat (ITT) analysis Week Robinson JG et al, N Engl J Med Apr 16;372(16):
51 ODYSSEY Long Term: Safety Analysis *Primary endpoint for the ODYSSEY OUTCOMES trial: CHD death, nonfatal MI, fatal and nonfatal ischemic stroke, and unstable angina requiring hospitalisation. Unstable angina requiring hospitalisation is limited to the UA events with definite evidence of progression of the ischemic condition (strict criteria). Robinson JG et al, N Engl J Med. 2015; 372: (suppl ):
52 ODYSSEY Long Term: Post-hoc Safety Analysis of Adjudicated Cardiovascular TEAEs No. patients at risk Cumulative probability of event Placebo Alirocumab Time (weeks) HR = 0.52 (95% C.I 0.31 to 0.90) p< Mean treatment duration: 70 weeks Endpoints: CHD death, MI, stroke, UA requiring hospitalization Robinson JG et al, N Engl J Med. 2015; 372: (suppl ):
53 ODYSSEY OUTCOMES: Study Design Estimated Completion: Jan 2018 Post-ACS (4-52 weeks) patients 1 age 40 yrs (n~18,000) with LDL-C 1.81 mmol/l, or ApoB 0.8 g/l, or Non-HDL-C 2.59 mmol/l despite high-intensity (or maximally tolerated) statin (atorvastatin mg or rosuvastatin mg/daily) x 2 wks ± other lipid-modifying therapy (e.g., ezetimibe, fenofibrate) 2 Randomization 3 Alirocumab 75 mg SC Q2wks x 2 months 150 mg SC Q2wks based upon Month 1 LDL-C 50 mg/dl (1.29 mmol/l) 4 Placebo SC Q2wks Follow-Up: Minimum 24 months or target number of events (~1600) estimated 11.4% rate at 4 yrs, 15% risk reduction; 90% power, 1-sided p=0.025, 1% lost 1 Elevated troponin or CK-MB or resting ECG changes + obstructive coronary disease (new/presumed new ischemia/infarction by perfusion imaging, regional wall motion abnormality, coronary stenosis 70% by angiography) 2 Key exclusion criteria: Uncontrolled hypertension; NYHA III-IV or LVEF<25%; prior hemorrhagic stroke; TG>4.52 mmol/l; hepatitis; egfr<30 ml/min 3 Following 2 wk (+ 5 days) run-in period with placebo (1 ml volume in an autoinjector) SC Q2wks 4 Titration downwards for very low LDL Schwartz et al Am Heart J 2014;168: e1; clinicaltrials.gov (NCT )
54 Do not copy or distribute Amgen Canada Inc. All rights reserved.
55 Do not copy or distribute Amgen Canada Inc. All rights reserved.
56 Do not copy or distribute Amgen Canada Inc. All rights reserved.
57 Do not copy or distribute Amgen Canada Inc. All rights reserved.
58 Do not copy or distribute Amgen Canada Inc. All rights reserved.
59 Do not copy or distribute Amgen Canada Inc. All rights reserved.
60 Do not copy or distribute Amgen Canada Inc. All rights reserved.
61 Do not copy or distribute Amgen Canada Inc. All rights reserved.
62 Do not copy or distribute Amgen Canada Inc. All rights reserved.
63 63
64 64
65 Do not copy or distribute Amgen Canada Inc. All rights reserved.
66 Do not copy or distribute Amgen Canada Inc. All rights reserved.
67 67
68
69 LDL-C evolocumab treated patients % Title 8 6 p= N= Pre-Treatment Post-Treatment
70 Administration Alirocumab Administration 1 injection SC q2wk, Doses: 75 mg or 150 mg* Auto-injector ALIROCUMAB ALIROCUMAB *As per the product monograph, measure LDL-C levels within 4 to 8 weeks of initiation or titration to assess response and adjust dose if needed Evolocumab Administration 1 injection SC q2wk, Dose: 140 mg 3 injections SC q4wk Total Dose: 420 mg Auto-injector Praluent Product Monograph. April 2016; Repatha Product Monograph. September
71 Individuals who may require lipid lowering strategies beyond statins Clinical ASCVD *1,2 Familial Hypercholesterolemia (FH) 3 According to the CCS Lipid Guidelines and AHA/ACC Guidelines, ASCVD may include one or more of the following: 1,2 Coronary heart disease Acute coronary syndrome History of myocardial infarction Stable or unstable angina Documented coronary disease Coronary or other arterial revascularization Cerebrovascular disease or transient ischemic attack Inherited conditions characterized by elevated LDL-C and resulting from mutations in genes involved in LDL-C metabolism 3 Heterozygous FH LDL-C >4.9 mmol/l Identification Elevated LDL-C with physical findings or a family history OR DNA-based evidence Homozygous FH Untreated LDL-C >13 mmol/l, CVD diagnosis on average at 20 years 3 Peripheral arterial disease Abdominal aortic aneurysm 2 *ASCVD, termed clinical atherosclerosis per CCS guidelines; typical levels when untreated; LDL-C level indicative, lower levels do not exclude HoFH. ACC, American College of Cardiology; AHA, American Heart Association; CCS, Canadian Cardiovascular Society; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol 1. Stone NJ et al. J Am Coll Cardiol. 2014;63: ; 2. Anderson TJ et al. Can J Cardiol Genest J et al. Can J Cardiol. 2014;30:
72
73 REVEAL study 73
74 SPIRE-2 study 74
75 Non-statin benefits agent study duration LDL-C placebo LDL-C treated ezetimibe IMPROVE-IT years % evolocumab FOURIER years % bococizumab SPIRE year % anacetrapib REVEAL years % Event rate reduction 75
76 agent Cost % LDL-C reduction yearly cost cost per % LDL-C reduction atorvastatin 80 mg generic 52% $ 142 $ 2.70 Lipitor 80 mg brand name 52% $ 1022 $19.65 rosuvastatin 20 mg generic 55% $ 124 $ 2.25 Crestor 20 mg brand name 55% $ 734 $13.35 ezetimibe 10 mg generic 21% $ 186 $ 8.85 Ezetrol 10 mg brand name 21% $ 788 $ PCSK9 inhibitors 65% $ 6800 $
77 Proposed algorithm Statin indicated conditions no 2016 targets LDL-C < 2.0 mmol/l *LDL-C < 1.8 mmol/l Patient stable? yes 2016 targets Consider lower targets LDL-C < 1.4 mmol/l IMPROVE-IT target LDL-C < 1.3 mmol/l REVEAL target LDL-C < 1.2 mmol/l SPIRE-2 target LDL-C < 0.8 mmol/l FOURIER target (GLAGOV) Sequence: 1) maximally tolerated statin 2) + ezetimibe [ + BAS (colesevelam)] 3) + PCSK9i
78 Inclisiran single dose 78 N Engl J Med 2016; Nov 13 online.
79 79
80 Effect of ISIS Treatment on Key Laboratory Values in the Three Study Patients. Volanesorsen: APOC3 inhibitor Gaudet D et al. N Engl J Med 2014;371:
81 Take home points 1. Guidelines: - LDL-centric; non-fasting lipids OK 2. Statins: - use first 3. Non-statins: - use ezetimibe next 4. PCSK9i: - alirocumab and evolocumab approved - HeFH and ASCVD not controlled - regression study positive - outcome study positive 5. Fibrates: - TG > 10 mmol/l pancreatitis prophylaxis - TG mmol/l study ongoing 81
82 82
83 Question 1 1. What is the current Canadian lipid target for high-risk patients? A) LDL-C < 2.0 mmol/l B) non-hdl-c < 2.6 mmol/l C) apo B < 0.8 g/l D) all of the above 83
84 Question 1 1. What is the current Canadian lipid target for high-risk patients? A) LDL-C < 2.0 mmol/l B) non-hdl-c < 2.6 mmol/l C) apo B < 0.8 g/l D) all of the above 84
85 Question 2 2. What is the main mechanism of statin benefit? A) LDL-C reduction B) anti-inflammatory C) anti-thrombotic D) endothelial relaxation E) all of the above 85
86 Question 2 2. What is the main mechanism of statin benefit? A) LDL-C reduction B) anti-inflammatory C) anti-thrombotic D) endothelial relaxation E) all of the above 86
87 Question 3 3. What is/are the current indication(s) for PCSK9 inhibition in Canada? A) familial hypercholesterolemia B) atherosclerotic cardiovascular disease, not controlled C) statin intolerance D) A and B only E) A, B and C 87
88 Question 3 3. What is/are the current indication(s) for PCSK9 inhibition in Canada? A) familial hypercholesterolemia B) atherosclerotic cardiovascular disease, not controlled C) statin intolerance D) A and B only E) A, B and C 88
89
90 Ultra-low issue #3: accuracy of LDL-C direct calculated 90 Quispe R et al. BMC Medicine : 83
91 Non-pharmacological LDL-lowering Compound Dose % LDL lowering Evidence level Isoflavones (soy protein powder) mg 3-11% A-I Soluble fibre 5-15 g 5-20% A-I Oatmeal 60 g 2-6% A-I Plant sterols 1.3 g 4-13% A-I AHA Step 2 diet 5-10% A-I Mediterranean diet 5-10% A-I Portfolio diet 10-20% A-I Almonds g 5% B-I Green tea extract 1.2 g 10% B-I High carb diet 60% of calories 5-10% B-I High protein diet 25% of calories 5-10% B-I Red yeast rice 1-2 g 7-20% A-IIa Guggulipid 100 mg 12% A-IIb Huang et al. Can J Cardiol 2011:
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationChallenges in lipid management
Challenges in lipid management Milan Gupta MD, FRCPC, FACC State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University of Toronto
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationCCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update. November 17 th, 2018
CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update November 17 th, 2018 Faculty/Presenter Disclosure Faculty: Rick Ward Relationships with commercial interests: Grants/Research Support:
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationNew Approaches to Lower LDL-C
New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationWhats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i?
Whats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More information2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty
Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationInvestigator Meeting. Monday, September 12, 2016
Investigator Meeting Monday, September 12, 2016 Principal Investigators Milan Gupta, MD, FRCPC, FACC Associate Clinical Professor of Medicine, McMaster University Brampton, ON Steering Committee David
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Fall Conference 2015 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationPraluent (alirocumab)
Praluent (alirocumab) Policy Number: 5.01.600 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Praluent
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationDYSLIPIDEMIA. Michael Brändle, Stefan Bilz
DYSLIPIDEMIA Michael Brändle, Stefan Bilz Cardiovascular risk in patients with DM Current guidelines with emphasis on patients with DM Familial Hypercholesterolemia PCSK9-inhibitors Primary Prevention
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More informationPCSK9 Inhibitors Current Status
PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Spring Conference 2016 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationThe Target is LDL, HDL not so much
The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationHYPERCHOLESTEROLEMIA
UPDATES ON HYPERCHOLESTEROLEMIA WITH EMPHASIS ON PCSK9 INHIBITORS July, 2018 Chicago by Ernesto L. Chua, MD, FACC, FACP, FPCP Board Certified in Internal Medicine Board Certified in Cardiology COL, USAF,
More informationGuidelines on Lowering LDL-C Levels
Scientific Insights Into LDL-C, PCSK9, and CV Risks High circulating LDL-C levels are associated with increased risk for ASCVD 1,2 Statin drugs interfere with cholesterol production, lowering serum LDL-C
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationDrug Class Prior Authorization Criteria PCSK9 Inhibitors
Drug Class Prior Authorization Criteria PCSK9 Inhibitors Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More information